Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Neoleukin Therapeutics, Inc. | d478892dex322.htm |
| EX-32.1 - EX-32.1 - Neoleukin Therapeutics, Inc. | d478892dex321.htm |
| EX-31.2 - EX-31.2 - Neoleukin Therapeutics, Inc. | d478892dex312.htm |
| EX-31.1 - EX-31.1 - Neoleukin Therapeutics, Inc. | d478892dex311.htm |
| EX-10.17 - EX-10.17 - Neoleukin Therapeutics, Inc. | d478892dex1017.htm |
| EX-10.16 - EX-10.16 - Neoleukin Therapeutics, Inc. | d478892dex1016.htm |
| 10-K - 10-K - Neoleukin Therapeutics, Inc. | d478892d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements Nos.333-194490, 333-203179, 333-210172 and 333-216572 on Form S-8 and Nos. 333-203180, 333-208651 and 333-215457 on Form S-3 of our report dated March 12, 2018, relating to the consolidated financial statements of Aquinox Pharmaceuticals, Inc. and subsidiary appearing in this Annual Report on Form 10-K of Aquinox Pharmaceuticals, Inc. for the year ended December 31, 2017.
/s/ Deloitte LLP
Chartered Professional Accountants
Vancouver, Canada
March 12, 2018
1